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Abstract
GM1 gangliosidosis and Morquio B disease are distinct disorders both clinically and biochemically yet they arise from the
same L-galactosidase enzyme deficiency. On the other hand, galactosialidosis and sialidosis share common clinical and
biochemical features, yet they arise from two separate enzyme deficiencies, namely, protective protein/cathepsin A and
neuraminidase, respectively. However distinct, in practice these disorders overlap both clinically and biochemically so that
easy discrimination between them is sometimes difficult. The principle reason for this may be found in the fact that these
three enzymes form a unique complex in lysosomes that is required for their stability and posttranslational processing. In this
review, I focus mainly on the primary and secondary L-galactosidase deficiency states and offer some hypotheses to account
for differences between GM1 gangliosidosis and Morquio B disease. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
De¢ciency in lysosomal L-galactosidase activity is
the primary defect in patients with GM1-gangliosi-
dosis, and in Morquio disease, type B. Clinical het-
erogeneity is a common feature of lysosomal dis-
eases, and GM1 gangliosidosis and Morquio
disease, type B represent the extremes in the spec-
trum of clinical phenotypes arising from mutations
in the L-galactosidase gene. Two related proteins
arise by alternate splicing of the primary L-galacto-
sidase transcript, the most abundant one being the
lysosomal L-galactosidase (Gal). The other, called
the L-galactosidase-like protein (S-Gal), does not dis-
play L-galactosidase activity and its speci¢c biologi-
cal action, tissue speci¢city and its role in the etiol-
ogy of these diseases is not well de¢ned. Gal activity
is also decreased to very low levels in galactosialido-
sis, a disorder resulting from de¢ciency in cathepsin
A/protective protein (PPCA), one important function
of which is to form a complex with Gal and a second
enzyme, Neuraminidase, whereupon these enzymes
are stabilized, or ‘protected’ from inappropriate ly-
sosomal proteolysis but allowed to undergo the post-
translational processing required for them to become
mature functional enzymes. In this review, I attempt
to de¢ne the pathophysiological basis for GM1-gan-
gliosidosis and Morquio disease by examining how
Gal works, the role of S-Gal, and the nature and role
of the complexes formed with PPCA and Neurami-
nidase. For completeness, a brief summary of the
current knowledge on galactosialidosis and sialidosis,
the primary neuraminidase de¢ciency will be in-
cluded.
2. Primary L-galactosidase de¢ciency diseases
2.1. The GM1-gangliosidoses
All patients with GM1-gangliosidosis have a
marked de¢ciency (0^5% of normal) of lysosomal
Gal activity [1,2]. In 1959, Norman and associates
reported an infant having a cherry red spot in the
fundus of the eye, with facial features reminiscent of
Hurler disease, but with no skeletal X-ray abnormal-
ity, with an enlarged liver, but no splenomegaly [3].
The nerve cell bodies of the neurons were ballooned
and foam cells with highly vacuolated cytoplasm was
noted in all visceral organs examined (liver, spleen,
lymph gland, thymus, bone marrow, lung, pancreas,
intestine, kidney, adrenal medulla, and thyroid).
Chemical analysis documented a 3-fold increase in
ganglioside sialic acid, but no further chemical char-
acterization was reported. Landing and co-workers
[4] described a series of eight clinically-similar pa-
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tients, in 1964, and from the ninth patient of the
series, O’Brien et al. isolated the storage substance
and showed it was GM1 ganglioside [5]. The ¢rst
indication of variable clinical expression was recog-
nized by Derry and co-workers, in 1968 [6], who
reported a French-Canadian boy who was clinically
well and had displayed appropriate milestones up to
the age of 11 months, noticeably lost these over the
next few months, and after a relentless downhill neu-
rodegenerative course, died at 4 years of age. Three
distinct phenotypic variants are now recognized ^ the
infantile form of Norman and Landing is now called
type 1, the late infantile/juvenile form is called type 2
and a later onset adult, chronic form is type 3. Type
1 patients, who usually die before the age of 3 years,
display the coarse facial features, hepatosplenomeg-
aly and the skeletal dysmorphology reminiscent of
Hurler’s disease, suggesting that if these patients
were to live longer their skeletal dysplasia would
likely be worse than that seen in Morquio disease.
Consistent with the extent of visceral organ involve-
ment, type 1 patients accumulate in these tissues and
ultimately excrete in their urine 30 or more L-linked
galactose-terminal oligosaccharides which arise from
the lysosomal digestion of a variety of glycoproteins.
On the other hand, patients with GM1 gangliosido-
sis, type 2 are characterized primarily as neuronal
lipidoses and while they do not display the skeletal
changes associated with type 1 they nonetheless ex-
crete elevated amounts of galactose-terminal oligo-
saccharides [6,7]. Neuropathological examination of
long-lived, enzymatically-proven type 2 patients has
documented accumulation of ceroid lipofuscin mate-
rial in addition to GM1 ganglioside in the brain [8].
Adult or chronic (type 3) GM1 gangliosidosis was
¢rst reported in 1977 by Suzuki et al. [9] who de-
scribed two Japanese patients (30 and 34 years of
age) with dysarthria, gait disturbance, dystonia and
visual impairment. Many more cases of type 3 have
been described in the Japanese and in other ethnic
groups, with clinical signs of both gray matter and
white matter involvement [10] (for a recent review,
see [11]) although there have been no complete de-
scriptions documenting accumulation of GM1 gan-
glioside in the brain of the type 3 form. A summary
of some of the major clinical and biochemical fea-
tures of the primary and secondary L-galactosidase
de¢ciencies is given in Table 1.
2.2. Morquio disease, type B
Classical Morquio disease is a rare autosomal re-
cessive disorder characterized by massive spondylo-
epiphyseal dysplasia (short stature, sternal protru-
sion, odontoid hypoplasia, severe genua valga),
normal intelligence and storage of keratan sulfate
(see Section 3 for structural properties). Two distinct
forms are recognized, the most common of which,
type A, results from a de¢ciency of N-acetylgalactos-
amine-6-sulfate sulfatase. The ¢rst indication of clin-
ical heterogeneity in Morquio disease was a case of a
14-year-old girl of Italian parents who was described
with a 4-year course of increasing limitation of mo-
tion, coxa vara, £attening of the femoral heads, and
narrowing of the intervertebral spaces, £attening of
the vertebral disks, and progressive dysplastic
changes [12]. Residual L-galactosidase activities in
¢broblasts were between 1.3 and 7.0% of the normal
with synthetic, and natural substrates. Although uri-
nary levels of keratan sulfate excretion were not
measured, Arbisser et al. [13] documented this in a
second case in 1977, and con¢rmed the enzyme de¢-
ciency. Later van Gemund et al. described three cases
in a single family [14], clearly establishing it as a
distinct variant and thereby enlarged the range of
clinical entities attributable to primary L-galactosi-
dase de¢ciencies. Patients with Morquio disease usu-
ally show normal intelligence in spite of neuropatho-
logical evidence of abnormalities [15] but neither
keratan sulfate nor GM1-ganglioside appear to be
stored in the brain [15]. Giugliani et al. [16] reported
a brother and sister who displayed mental regression
and the skeletal abnormalities of Morquio B
with keratan sulfaturia and oligosacchariduria,
thus obscuring the lines of clinical demarcation be-
tween GM1 gangliosidosis and Morquio disease,
type B.
3. Secondary L-galactosidase de¢ciencies
3.1. Galactosialidosis
Galactosialidosis as the name implies arises from
the simultaneous de¢ciencies of L-galactosidase and
neuraminidase (also called sialidase). These de¢cien-
cies are the secondary consequences of primary de-
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fects in another lysosomal enzyme, Protective pro-
tein-cathepsin A (PPCA). In a review in 1994 [17]
we summarized the major clinical ¢ndings of 55
cases, documented the major clinical features of the
infantile, late infantile, juvenile and adult cases of
galactosialidosis and described the salient biochemi-
cal features. A more recent review has also appeared
[18]. The majority of cases described to date are ex-
amples of the juvenile/adult variant where coarse fa-
cial features, mental retardation, cherry-red spots,
myoclonus, and ataxia are the dominant ¢ndings.
In the relatively few early infantile cases that have
been noted at birth or soon after birth, ascites,
coarse facies, bony deformities, and hepatosplenome-
galy are consistent ¢ndings. Several recent cases of
early infantile Galactosialidosis have been described
where nonimmune hydrops fetalis was diagnosed by
ultrasound between the 24th and 28th week of ges-
tation [19^22]. At birth, all infants presented with
massive edema, £attened coarse facial features, with
no or with mild dysostosis multiplex. Vacuolated
lymphocytes were noted in all cases. Diagnosis was
con¢rmed by the presence of sialyloligosaccharides in
the urine, de¢cient L-galactosidase in peripheral
blood leukocytes (due to its instability, neuramini-
dase is not usually measured reliably in leukocytes)
and de¢ciency of both L-galactosidase and neurami-
nidase in cultured skin ¢broblasts.
Table 1
Di¡erential diagnosis of L-galactosidase and neuraminidase de¢ciencies
Disorder Enzyme
de¢ciency
Onset Symptoms Diagnosis Genetics
GM1
gangliosidosis
L-Galactosidase
(EC 3.2.1.23)
1. Infantile
(birth to 6 months)
Facial dysmorphism, organomegaly,
dysostosis multiplex, cherry-red spots,
developmental retardation
1. Oligosaccharides
in urine
AR
Chr 3p21.3
2. Juvenile Onset of symptoms delayed,
progression slower
2. L-Galactosidase
de¢ciency in leukocytes
and ¢broblast cultures
3. Adult Ataxia, dysarthria, mild to moderate
intellectual deterioration, skeletal
changes
Galacto-
sialidosis
Primary:
cathepsin A
(EC 3.4.16.1)
1. Early infantile
(prebirth^6 months)
Hydrops fetalis, skeletal dysplasia,
developmental retardation
1. Sialyloligosaccharides
in urine
AR
Chr 20q13.1
Secondary:
neuraminidase,
L-galactosidase
2. Late infantile
(6^12 months)
Organomegaly, cherry-red spots,
dysostosis multiplex, mild mental
retardation
2. Cathepsin A
de¢ciency or
3. Juvenile Dysmorphism, corneal clouding,
skeletal dysplasia, cherry-red spots,
progressive neurologic deterioration,
dementia
3. Neuraminidase and
L-galactosidase de¢ciency
in ¢broblast cultures
Sialidosis Neuraminidase
(sialidase)
(EC 3.2.1.18)
1. Early infantile Hydrops fetalis, organomegaly,
failure to thrive, death within
12 months
1. Sialyloligosaccharides
in urine
AR
Chr 6p21.3
2. Late infantile
(6^12 months)
Coarse facial appearance,
organomegaly, motor retardation,
progressive neurologic
deterioration, renal involvement,
death in early childhood
2. Neuraminidase
de¢ciency in ¢broblast
cultures
3. Juvenile Hurler-like phenotype, progressive
neurologic deterioration
4. Adult Begins in adolescence, myoclonus,
bilateral cherry-red spots,
visual loss, normal intelligence
AR, autosomal recessive.
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3.2. Sialidosis, a primary neuraminidase de¢ciency
Sialidosis is due to a primary de¢ciency in neur-
aminidase [23]. As in galactosialidosis, sialyloligosac-
charides are excreted in the urine, and it is impossible
to distinguish the two disorders on this basis alone.
Analysis of cultured skin ¢broblasts is needed to dis-
criminate between the two. Early infantile and infan-
tile cases of sialidosis present with hydrops fetalis,
and coarse facial features and are di⁄cult to distin-
guish from comparable cases of GM1 gangliosidosis
and galactosialidosis. As in GM1 gangliosidosis and
galactosialidosis, sialidosis occurs in clinically dis-
tinct forms but the major signs overlap considerably
and complete delineation of these three distinct enti-
ties should include both enzyme assays and separa-
tion of urinary oligosaccharides (Table 1).
4. Storage substances
4.1. GM1-gangliosidosis and Morquio disease, type B
GM1 ganglioside is one of the major gangliosides
in both the newborn and mature brain and usually
comprises about 25% of the total ganglioside sialic
acid. In types 1 and 2, GM1 gangliosidosis, the total
ganglioside content in gray matter increases 3^5-fold
and GM1 makes up about 80% of the total; thus the
accumulation of this ganglioside is about 12^20-fold
over the control values [7,11,24,25]. GM1 ganglioside
has been isolated from puri¢ed myelin, and the ele-
vated content in white matter likely arises from this
membrane and the neuronal elements contaminating
white matter preparations [25]. In adult, chronic
GM1 gangliosidosis, mild GM1 ganglioside accumu-
lation has been documented in the gray matter
[26,27] and in the basal ganglia particularly the cau-
date nucleus and the putamen [26^28]. In the visceral
organs, particularly the liver, GM1 ganglioside con-
tent is markedly elevated over the normal concentra-
tion but ganglioside content in this tissue is small
compared to the brain [25]. Concordant with GM1
ganglioside accumulation is the storage of the non-
sialylated glycolipid GA1 in all three types of GM1
gangliosidosis [11,28].
At least 42 di¡erent glycoprotein-derived galac-
tose-terminal oligosaccharides have been isolated
from urine of types 1 and 2 GM1 gangliosidosis
[11,29,30]. Storage of undersulfated forms of keratan
sulfate, a galactose-containing glycosaminoglycan
and a substrate for L-galactosidase, has been docu-
mented in the infantile form of GM1 gangliosidosis
but its impact on the severity and progression of the
disease is regarded as minimal compared to that of
GM1-ganglioside [7,11,31]. It is noteworthy that
both the degree of accumulation and the chemical
composition of these keratan sulfate-like materials
are di¡erent from those found in full-blown Morquio
disease.
In Morquio disease, type B, the major storage
substance is keratan sulfate, characterized by the
repeating poly(N-acetyllactosamine) sequence of
^3GalL1ÿ4GlcNAc1^ which is sulfated on the C6 po-
sition of both residues but more commonly on the
GlcNAc. Two types of keratan sulfates (KS1 and
KS2) are known [32^34]. KS1 found in the cornea
is longer (Mr 10 000^26 000) and the polysaccharide
is linked to the amide N of asparagine while KS2
(Mr about 5000) found in skeletal tissues and carti-
lage is O-linked via N-acetylgalactosamine to either
serine or threonine. Both skeletal and corneal forms
of keratan sulfate are present in the urine of Mor-
quio disease patients. There have been few detailed
analyses of Morquio disease brain and additional
neuropathological studies are needed to con¢rm
that neither keratan sulfate nor GM1-ganglioside
are stored in the brain [15].
4.2. Galactosialidosis and sialidosis
Urinary excretion of sialyloligosaccharides is the
biochemical hallmark of both galactosialidosis and
sialidosis, and this is totally ascribable to the neur-
aminidase de¢ciency, be it primary or a secondary
enzyme defect. These substances arise largely from
the lysosomal degradation of asparagine-linked gly-
coproteins [17,18]. Sialyloligosaccharides arising
from degradation of the serine and threonine-O-
linked oligosaccharides have not been characterized
[17,18]. The abundance of the respective mono-, di-,
tri-, and tetrasialylated oligosaccharides found in
urine and other body £uids re£ect the relative distri-
bution of these polyantenna-containing glycoprotein
precursors produced in the body. Both K2^6 and K2^
3 linked sialylated termini have been characterized,
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with the K2^6 structure being relatively more abun-
dant in sialidosis. Although some galactose-terminal
oligosaccharides have been characterized in galacto-
sialidosis, it is likely that they have arisen from in-
complete chain elongation during biosynthesis rather
than from partial digestion due to residual neurami-
nidase activity.
One of the most surprising ¢ndings to date is the
relative lack of storage of the polysialogangliosides in
the brain in both galactosialidosis and sialidosis. This
suggests that the neuraminidase de¢ciency character-
ized in these disorders has a higher degree of specif-
icity for sialyloligosaccharides attached to glycopro-
teins than the comparable structures attached to the
ceramide backbone of gangliosides. The sialyl K2^3
linkage to galactose is more abundant in ganglio-
sides, compared to the ganglioside K2^8 linkage,
and may be both terminal and internal whereas in
glycoproteins the sialyl K2^3 linkage to galactose is
always terminal. Since the ceramide backbone is de-
graded only after the carbohydrate linkages have
been removed whereas in the case of glycoproteins,
the protein backbone can be largely degraded inde-
pendent of the digestion of the carbohydrate, it is
conceivable that a ganglioside speci¢c neuraminidase
exists that is both separate and distinct from the
glycoprotein or oligosaccharide neuraminidase in-
volved in these two diseases. There has been some
recent evidence that this is the case and it would
account for the lack of ganglioside storage in the
brain in these diseases [35]. There is evidence for
slight accumulations of the major monosialoganglio-
sides, and GD1a ganglioside in spinal cord neurons
in galactosialidosis patients but these accumulations
may re£ect non-speci¢c disease-related changes as
accumulations of similar gangliosides, particularly
the monosialogangliosides have been documented in
a variety of other disorders, such as Niemann^Pick
disease, Hurler disease and other non-ganglioside,
non-neuraminidase related disorders [36].
5. L-Galactosidase and elastin binding protein arise
from the Gal gene by alternate splicing
The human Gal gene, localized on chromosome
3p21.33 [37^39], is 62.5 kb in length and is composed
of 16 exons [40,41]. The intron/exon junctions have
been de¢ned and a long intronic region occurs be-
tween exons 1 and 2 (22 kb in the human). The
mouse Gal gene (80 kb) and that of the dog also
contain 16 exons [42^44]. Morreau et al. [40] de-
scribed two transcripts in human ¢broblasts, where-
by the larger (2.4 kb) and 12-fold more abundant
mRNA encoded the full length lysosomal Gal while
the minor form (2.0 kb) was an alternately spliced
Gal-like protein (which we have named S-Gal). The
general structural features of both proteins are
shown in Fig. 1. Yamamoto et al. [39] and ourselves
[45] have independently con¢rmed the existence of
this alternate transcript and we have described its
properties [45^52].
5.1. Biosynthesis and processing of Gal
The Gal gene encodes a 677 amino acid prepropo-
lypeptide, where a 23 amino acid N-terminal signal
sequence is cleaved on entry into the ER to generate
a propolypeptide of 654 residues. Gal is glycosylated
co-translationally to an 84 kDa precursor and when
phosphorylated is 88 kDa. It has 8 cysteine residues
(likely forming 4 cystines), and 7 consensus putative
Fig. 1. Features of Precursor Gal, mature, fully-processed Gal
and S-Gal. The downward arrows identify the putative N-glyco-
sylation sites (at N26, N247, N464, N498, N542, N545, and
N555, where only one of N542 and N545 is likely to be occu-
pied). The upward arrows show 14 sites of missense mutations
and the horizontal bars identify the two duplication sites.
Arg530 has been proposed as the C-terminal of the mature fully
processed Gal protein, which would have resulted in the loss of
123 residues, 3 putative N-glycosylation sites, and two cysteine
residues (which are postulated to form a disul¢de bond).
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N-glycosylation sites although it is unlikely that all
are occupied [53] as two are side-by-side (Asn542Ser-
SerAsnTyrThr547) and steric hindrance may block
glycosylation of the one if the other is occupied
(Fig. 1). Zhang et al. [53] puri¢ed this Gal precursor
to apparent homogeneity and characterized its struc-
tural and kinetic properties. It displayed the same
speci¢c activity (0.7 mmol/h per mg) as the mature
form of the enzyme puri¢ed from placenta, it was a
monomer on molecular sieve chromatography and
had an Mr of 88 000 on sodium dodecyl sulfate^poly-
acrylamide gels. It had the same pH optimum (pH
4.3) and displayed kinetic constants with synthetic
substrates identical to the mature placental enzyme,
although since no studies have appeared it is unclear
whether the precursor has the capacity to hydrolyze
natural substrates. The puri¢ed precursor was endo-
cytosed from the medium and corrected the defect in
GM1-gangliosidosis ¢broblasts, indicating the re-
combinant precursor is phosphorylated and man-
nose-6-phosphate targeted to lysosomes, was con-
verted to a 72 kDa polypeptide upon digestion with
N-glycanase, and to a 50 kDa form on digestion with
pepsin (no thiol reagents; Withers and Callahan, un-
published observations).
Pulse-chase studies in human ¢broblasts have
shown the Gal precursor is translocated to the endo-
somal^lysosomal compartment via the mannose-6-
phosphate receptor and is processed in a few hours
to the mature enzyme, the monomer of which is 64
kDa [54^60]. Maturation to the 64 kDa enzyme oc-
curs by processing only at the C-terminal end of the
protein in normal ¢broblasts both in the presence
and absence of leupeptin, a potent inhibitor of thi-
ol-proteases such as cathepsin B, S, H, and L, indi-
cating that normal maturation does not depend on
this class of cathepsins (Fig. 2). In galactosialidosis
¢broblasts, little normal maturation of L-galactosi-
dase occurs. We have detected two abnormal early
cleavage steps in L-galactosidase C-terminal process-
ing, resulting in the appearance of either an 80 kDa
species alone or together with a 72 kDa species [59].
Generation of the 80 kDa species is inhibited in the
presence of leupeptin, but the appearance of the 72
kDa species is not a¡ected by leupeptin (Fig. 2). The
precise locations for this inappropriate processing
has not been de¢ned but examination of the deduced
L-galactosidase sequence reveals a putative thiol pro-
tease cleavage site at Arg595 (a cathepsin B site re-
quires a proximal hydrophobic residue; in this case
Ala is at 594). In vivo, normal maturation of L-gal-
actosidase requires its association in a complex (this
is discussed below) that protects this susceptible site
but does not prevent a non-thiol protease from gen-
erating the mature, fully-processed Gal. Mature Gal
is subsequently degraded and we have identi¢ed 18
kDa and 50 kDa digestion products. Interestingly, in
I-cell ¢broblasts, only the Gal precursor and the 18
kDa fragment could be detected suggesting that a
portion of the 18 kDa fragment could have arisen
by non-lysosomal proteolysis [59].
5.2. Gal: substrates, the role of saposin B, and its
active site
Gal releases terminal L,1^4 or L,1^3 linked galac-
tose residues from the glycosphingolipids (GM1 gan-
glioside, a major acidic lipid of brain gray matter,
lactosylceramide, and gangliotetraosylceramide (asia-
loGM1 ganglioside)), galactose-terminal neutral oli-
Fig. 2. Posttranslational processing of the Gal precursor and
the proposed role of protective protein. The propolypeptide pre-
cursor is folded and N-glycosylated in the endoplasmic reticu-
lum. The precursor is fully active (with synthetic substrates)
and may account for the small amount of residual activity de-
tected in most cells, although there is a small amount of immu-
noreactive material that migrates like the mature form of the
enzyme. Normal processing requires Gal to enter into a com-
plex with protective protein and neuraminidase whereupon the
protein is processed at its C-terminal end to form the mature
enzyme. The enzyme is degraded by resident proteases, with the
appearance of 18 kDa and 50 kDa fragments. Since the same
18 kDa fragment is found in both normal ¢broblasts and in
galactosialidosis ¢broblasts, it can be assumed that this poly-
peptide arises upon digestion of the heretofore unprocessed N-
terminal end of the protein.
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gosaccharides (either attached to a protein core as in
glycoproteins or free in solution), and keratan sul-
fate-derived oligosaccharides [11,61^64] accumulat-
ing in GM1 gangliosidosis and Morquio disease,
type B. Substrate speci¢city studies have used mature
forms of Gal puri¢ed from human liver or placenta,
rabbit brain, or other tissue sources. In vitro hydrol-
ysis of GM1 ganglioside and lactosylceramide re-
quired detergents (such as cutscum, or taurocholate).
In vivo, a small 80 amino acid N-glycosylated poly-
peptide, saposin B (Fig. 3), which binds to the cer-
amide (lipid) moiety of GM1 ganglioside stimulates
conversion of GM1 to GM2 ganglioside (for reviews,
see [65,66]). Zschoche et al. [64] recently showed that
both saposin B and C stimulated hydrolysis of lip-
osomal lactosylceramide by Gal. Saposins B and C
arise from proteolytic intralysosomal digestion of the
parent, prosaposin, a 69 kDa prepropolypeptide
(Fig. 3). Saposin B interacts directly with the ceram-
ide moiety to form a 1:1 water soluble lipid^protein
complex. It also binds sulfatide and stimulates its
hydrolysis by arylsulfatase A [65,66]. Neither deter-
gents, saposin B nor prosaposin, are known to be
involved in the hydrolysis of galactose-terminal oli-
gosaccharides. Of the three mutations known to oc-
cur in saposin B, none give rise to GM1 gangliosi-
dosis or Morquio disease phenotypes. In patients
with Morquio, type B, the residual Gal hydrol-
yzes substrates with Km values severalfold higher
than normal [67,68]. Yutaka et al. [69] showed in
1982 that Gal-L-N-acetylglucosamine-(6-sulfo)-L-
[1-3H]galactitol, a trisaccharide derived from keratan
sulfate, was cleaved by crude ¢broblast Gal but there
have been no further studies with this substrate.
The Gal precursor cleaves the usual £uorogenic
and colorimetric synthetic substrates and undergoes
rapid inactivation upon cleaving the mechanism-
based suicide substrate 2,4-dinitrophenyl-2-£uoro-2-
deoxy-L-D-galactoside (DNP-FDG) [53]. These re-
sults demonstrated that Gal cleaves substrates by a
Koshland double-displacement mechanism with a
nucleophilic attack by an acidic catalytic site nucle-
ophile (Glu or Asp) with L-con¢guration retention
and formation of a galactosyl-enzyme intermediate
[53] (Fig. 4). There have been no studies using the
precursor Gal with natural substrates. Using the sui-
cide substrate, electrospray ionization mass spec-
trometry after pepsin digestion (+thiol agents) and
HPLC separation of peptides [70], we [71] identi¢ed
the galactosylated-nucleophile as Glu268, a residue
which is completely conserved among 6 other known
Fig. 3. Saposin B, a posttranslational proteolytic product of
Prosaposin. The Prosaposin prepropolypeptide of 524 amino
acids, after removal of a 16 amino acid signal peptide is N-gly-
cosylated and directed to the endosomal^lysosomal compart-
ment whereupon it is processed by lysosomal proteases into a
series of smaller products which have been called saposin A^D.
Fig. 4. Catalytic mechanism of a L-con¢guration retaining fam-
ily 35 L-galactosidase.
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Gal sequences (Fig. 5). Analogous to the acid-acid
mechanism of other glycosidases including Escheri-
chia coli Gal [72,73], the residue required to cleave
this bond and restore Gal to an active state is likely a
conserved acidic residue. Of the other acidic residues
in mature human Gal, only Glu186, Glu188, Glu339,
and Asp332 are completely conserved among the
same six enzymes (Fig. 5). We converted Glu268 to
Gln and this form of Gal, puri¢ed from perma-
nently-transfected CHO cells, was catalytically inac-
tive con¢rming the role of Glu268 in the mechanism
(Callahan and Zhang, unpublished observations).
We have now identi¢ed a naturally-occurring muta-
tion in Asp332 (it is converted to Asn332) and using
the same CHO expression system have evidence that
this residue is involved in the active site although it is
too early to assign it a role in the catalytic mecha-
nism (such as for cleavage of the galactosyl^Glu268
bond to release free galactose and restore the enzyme
to an active state [74]).
5.3. S-Gal, a component of the elastin binding (EBP)
receptor?
The second product of the Gal gene, S-Gal, arises
by alternate splicing of the primary Gal transcript
whereby exons 3, 4 and 6 are skipped, and there is
a frameshift in exon 5 (which encodes a unique 32
amino acid sequence) [40]. The reading frame is re-
stored at the start of exon 7. S-Gal has 546 amino
acids, a predicted mass of 60 000 and an apparent
mass in the range 67 000^69 000 (depending on the
number of occupied N-glycosylation sites). Three
cysteines are removed during the alternate splicing
process but a new Cys occurs at position 87 in the
frameshifted unique part of the sequence to restore
an even number. Except for the area where splicing
occurs, S-Gal is identical to the wild-type Gal and
although there is no di¡erence in the number of N-
glycosylation sites between Gal and S-Gal, the latter
was localized to the perinuclear area of the cyto-
plasm but not to lysosomes [40,45]. It is unclear if
S-Gal occurs in the mouse [43] but an alternately
spliced transcript was not detected in the dog [44].
Elastin binding glycoprotein (also called EBP), a
67 kDa glycoprotein, was originally identi¢ed in
sheep and found to be a component of the elastin
binding receptor [46]. Based on immunological and
ligand binding studies we found that human S-Gal
and sheep EBP were related. Sheep EBP contains a
lactose (i.e., a L-galactoside) binding site and it binds
to an a⁄nity column containing the ligand,
GSPSAQDEASPL, a portion of the unique sequence
found in human S-Gal [49^51]. Sheep EBP is one of
three proteins (the others are 54 kDa and 61 kDa)
that form a cell surface receptor the major function
of which is to facilitate the formation of extracellular
elastin matrix by binding tropoelastin, the elastin
monomer, and deliver it to the cell surface where it
is released in the presence of galactosugars (Fig. 6).
The 54 kDa and 61 kDa proteins serve as the mem-
brane anchors while the EBP can be dissociated from
and re-associate with the rest of the receptor. Neither
of the 54 kDa or 61 kDa proteins has been well
characterized at least in sheep. Inside cells, EBP is
postulated to serve a ‘chaperone-like’ function for
correct targeting of tropoelastin, the elastin mono-
mer. Human S-Gal has functional similarity to the
EBP from sheep aortic smooth muscle cells. Our af-
¢nity-puri¢ed anti-S-Gal antipeptide antibody recog-
Fig. 5. Conserved acidic residues of homologous L-galactosi-
dases.
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nized sheep EBP both on western blots [50,51] and in
sections of sheep aorta tissue and a similar protein in
human placenta, muscle and kidney (Hinek and Call-
ahan, unpublished observations). Thus we were the
¢rst to show that S-Gal is related to the elastin bind-
ing protein (EBP). We have recently shown that the
majority of EBP residing on the cell surface can be
internalized to endocytic compartments but not to
lysosomes and can be recycled back to the cell sur-
face within 45^60 min. To de¢ne further the genetic
origin of human EBP, we isolated and characterized
a full length human S-gal cDNA clone, and ex-
pressed it in COS-1 cells and in the EBP-de¢cient
smooth muscle cells (SMC) from sheep ductus arte-
riosus (DA) [45]. In vitro translation yielded an un-
glycosylated form of S-gal which immunoreacted
with anti-L-galactosidase antibodies and bound to
elastin and laminin a⁄nity columns. S-gal cDNA
transfections into COS-1 and DA SMC increased
expression of a 67 kDa protein that immunolocalized
intracellularly and to the cell surface and, when ex-
tracted from the cells, bound to elastin. The S-gal
transfected cells displayed increased adherence to
elastin-covered dishes, consistent with the cell surface
distribution of the newly produced S-gal-encoded
protein. Transfection of DA SMC additionally cor-
rected their impaired elastic ¢ber assembly. These
results conclusively identify the 67 kDa splice variant
of L-galactosidase as EBP. Further immunological
studies show the human and sheep elastin binding
receptor contain in addition to S-Gal, the same two
major proteins; namely, protective protein/cathepsin
A and neuraminidase [52].
6. Neuraminidase
Lysosomal neuraminidase is a 45.5 kDa prepropoly-
peptide of 415 amino acids, with a signal peptide of
45^47 amino acids (consisting of a positively charged
amino terminal region (residues 1^18) and a central
hydrophobic area (residues 19^38)), and is posttrans-
lationally-glycosylated (it contains three potential N-
glycosylation sites) and processed to a mature 48.3
Fig. 6. The role of S-Gal (elastin binding protein) in formation of extracellular matrix.
BBADIS 61880 10-9-99
J.W. Callahan / Biochimica et Biophysica Acta 1455 (1999) 85^10394
kDa protein [75,76]. It is not clear if the neuramini-
dase precursor is active or whether it requires a pro-
teolytic activating event but results to date indicate
that minimal posttranslational protein processing oc-
curs, only at the N-terminal. Homology predictions
indicate signi¢cant relatedness of the human enzyme
to viral, bacterial, protozoan, and rodent neuramini-
dases and consists of six four-stranded antiparallel L-
sheets arranged around a central axis of symmetry
containing the active site. Neuraminidase is found in
both lysosomal and plasma membranes and it is
readily secreted from cells [77]. Sequence predictions
suggest it does not contain a hydrophobic sequence
that resembles a transmembrane domain. However,
expression studies have shown that shortly after
neuraminidase arrives in the ER, it associates with
PPCA which serves as a protein-speci¢c ER chaper-
one for neuraminidase [76,77] and accompanies it
through the Golgi and endosomal-lysosomal com-
partments. Metabolic labeling studies have indicated
that at least a portion of neuraminidase is poorly
phosphorylated and may not be recognized by the
mannose-6-phosphate receptor [78]. Association
with PPCA in the ER obviates this relative lack of
lysosomal targeting capability. Mutations described
to date which have been identi¢ed in either type I or
type II forms of sialidosis include: a homozygous 4
base pair duplication (+ACTG8^11) resulting in an
early frameshift, a single base deletion from codon
Ser403 which shifts the reading frame to include an
additional 69 amino acids beyond the usual termina-
tion after codon 415, a chain terminating mutation
(G1258T, Arg377ter) and three missense mutations
(T401G, Leu91Arg; T779A, Phe260Tyr and
T1088C, Leu303Pro) [75,76]. The gene for neurami-
nidase has been localized to chromosome 6p21.3. Ex-
pression in COS-1 cells of the frameshifted Ser403
and the Arg377ter mutations resulted in misfolded
proteins that did not exit the ER.
7. Protective protein/cathepsin A
Protective protein/cathepsin A is synthesized as a
54 kDa propeptide zymogen which when processed
in lysosomes is cleaved into 32 kDa and 20 kDa
components (held together via interchain disul¢de
bonds) and displays serine protease activity (where-
upon it becomes mature cathepsin A). PPCA was
originally thought to function only to ‘protect’ Gal
and Neuraminidase from intralysosomal digestion by
forming a complex with these enzymes in lysosomes
but site directed mutagenesis and expression studies
[79^81] have shown that the serine protease activity
can be abolished without a¡ecting its ability to ‘pro-
tect’ Gal and Neuraminidase from intralysosomal
proteolysis. Studies on related proteases, yeast car-
boxypeptidase Y, and mouse cathepsin L [82,83],
suggest that the lack of protease activity in the pre-
cursor is partly due to a N-terminal propeptide intra-
molecular chaperone which promotes folding of the
protein (for a review, see [84]) such that the propep-
tide region blocks proteolytic cleavage at the site
between the 32 and 20 kDa peptides until a confor-
mational change occurs presumably upon its associ-
ation with either Gal or neuraminidase. Elsliger and
Potier [85], using model structures, speculated that
protective protein was a dimer with the N-terminal
propeptides near the surface consistent with its abil-
ity to serve as an intramolecular chaperone [83]. Ru-
denko et al. [86,87] also used an atomic model para-
digm of the PPCA to examine the structure-function
relationships in the protein and predicted that 9 of
the currently de¢ned 11 mutations [88^92] in PPCA
(Table 2) drastically altered the folding and stability
of the protein, while the remaining two caused less
severe alterations of the protein. None of the muta-
tions identi¢ed to date involves the active site ser-
ine150 or the two other required residues (His429,
and one of Asp370 or Asp372) [18,87]. Since severe
de¢ciencies of both Gal and neuraminidase always
accompanied these mutations, and since PPCA and
neuraminidase associate in the ER [78] it can be cor-
rectly assumed that PPCA carrying these mutations
does not exit the ER either alone or in conjunction
with neuraminidase.
8. The ‘complexes’ formed by Gal and S-Gal with
protective protein/cathepsin A and neuraminidase
8.1. The lysosomal complex
Upon arriving in the endosomal-lysosomal com-
partment, Gal associates with the pre-associated
PPCA and neuraminidase to form a complex that
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is absolutely essential for its stabilization and for its
normal posttranslational processing to its mature
form (Fig. 2). Recently, Pshezhetsky and Potier [93]
isolated a 1.27 MDa form of the complex that con-
tained, in addition, N-acetylgalactosamine-6-sulfate
sulfatase, the enzyme de¢cient in Morquio disease
type A, and showed that its activity was also reduced
in galactosialidosis. This correlates with elevated lev-
els of keratan sulfate in the urine of galactosialidosis
patients. These ¢ndings suggest that storage of ker-
atan sulfate in both types A and B Morquio disease
result from the combined e¡ects of the direct muta-
tions in N-acetylgalactosamine-6-sulfate sulfatase
and Gal, respectively, which a¡ect complex forma-
tion and stability [93,94]. Unlike neuraminidase
which undergoes minimal posttranslational process-
ing, substantial processing of Gal occurs at the C-
terminal end of Gal which contains the most hydro-
philic sequence of the entire protein and a postulated
‘intramolecular chaperone’ that is essential for cor-
rect folding in the ER and Golgi, but is not required
for catalytic activity [59,60]. This region of the en-
zyme (comprising residues 653^666) is relatively pro-
line-rich and may serve to facilitate protein-protein
interaction with protective protein, thus blocking a
putative thiol protease susceptible site at R595.
When the C-terminal is lost after lysosomal process-
ing (Fig. 2), this stabilizing function is replaced by
the ‘Complex’ which also facilitates Gal dimerization
and oligomerization. Since the 88 kDa Gal precursor
is a monomer, and fully active, it must be folded into
an active conformation prior to its release from the
ER and does not require protective protein for its
transit through the Golgi, its lysosomal localization,
Table 2
Protective protein/cathepsin A mutations
Residue/mutationa Sequence conservedb Other allele Mutation e¡ect Ref.
GROUP 1: Group 1 mutations give severe disease except when the second allele is from Group 2, but none involve active site resi-
dues; they destabilize protein folding and stability, and the resultant protein is unlikely to exit the ER
Q49R/152AsG F440V Mild [87,88]
Q49R/152AsG SpDEx7 Mild [87,88]
S51Y/158CsA H,M,C,W,Y +grp1 Severe [87,88]
W65R/199TsC H,M,C,W,Y F411V Mild [87,88]
W65R/199TsC H,M,C,W,Y SpDEx7 Mild [87,88]
S90L/274-5TCsCT H,M,C,W,Y +grp1 Severe [87,88]
V132M/400GsA H,M,C,W,Y +grp1 Severe [87,89]
L236P/713TsC H,M,C,W,Y +grp1 Severe [87,89]
Y395C/1190AsG H,M,C,W,Y +grp1 Severe [87,88,92]
M406T/1223TsC F440V Mild [87,89]
M406T/1223TsC SpDEx7 Mild [87,89]
G439S/1321GsA H,M,C,W,Y +grp1 Severe [87,89]
GROUP 2: a¡ect dimerization; monomer is rapidly degraded
Y249N/751TsA H,M,C, +grp2 Mild [87,88]
F440V/1324TsG H,M,C, +grp2 Mild [87,89]
GROUP 3: a¡ect RNA stability and abundance; markedly decreased amounts of PPCA
SpDEx7 SpDEx7 Mild [87,88]
+grp2 Mild [87]
+grp1 Not known [87]
dC118 Y249N/751TsA Not known [89]
c517delTT IVS+9CsG Mild [91]
aAll amino acids are numbered from the initiating methionine and from the ¢rst base of the codon which is position +7 of the
cDNA.
bThese residues are conserved in the human (H), mouse (M), and chicken (C) PPCAs, and wheat (W) and yeast (Y) serine carboxy-
peptidases.
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nor for its secretion from cells [53,95,96]. The major-
ity of studies on the complex to date have focused on
the role played by the protective protein in the stabil-
ization and oligomerization of Gal. However, based
on our recent work [59,60] it seems clear that the
fully processed PPCA is partly responsible for the
C-terminal processing of Gal precursor to the mature
form but it is not known why processing stops when
Gal is about 64 kDa in size (Fig. 2). Although PPCA
and neuraminidase associate in the ER and travel
together through the intracellular compartments, it
is unclear if neuraminidase displays catalytic activity
prior to its localization in the acidi¢ed endosomal-
lysosomal compartment. Vinogradova et al. [77] have
recently shown that activation of neuraminidase ac-
tivity coincides with its occurrence in the mature high
molecular mass complex found in lysosomes and
without this association, neuraminidase undergoes
rapid and irreversible proteolysis.
8.2. The elastin binding receptor
As mentioned above we have presented evidence
that the alternately spliced form of Gal, S-Gal, is
identical to the 67 kDa elastin binding protein, the
major function of which is to assist in the delivery of
tropoelastin to the cell surface [45,49^51] and that
the elastin binding receptor is formed from S-Gal,
PPCA and neuraminidase. Release of newly secreted
tropoelastin molecules from the association with S-
Gal occurs upon interaction between it and galacto-
sugar moieties protruding from the carbohydrate
chains of glycoproteins thus facilitating formation
of the micro¢brillar sca¡old of elastic ¢bers. Studies
are now under way examining elastic ¢ber assembly
by ¢broblasts from patients with GM1 gangliosido-
sis, Morquio disease, type B, galactosialidosis, and
sialidosis. Our initial results in ¢broblasts have found
that most but not all GM1 cell lines have the ca-
pacity to assemble elastic ¢bers while cells from pa-
tients with Morquio disease type B do not (all the
Gal mutations in these cells have been de¢ned). In
addition we noted that cells from patients with ga-
lactosialidosis and sialidosis also do not assemble
elastic ¢bers [52]. These data are in accord with the
recent ¢ndings that newly synthesized PPCA and
neuraminidase associate in the ER, are secreted to-
gether and reside in the plasma membrane [76,78]
and are in agreement with our earlier data [49,50].
9. Genetic heterogeneity in GM1 gangliosidosis and
Morquio disease, type B
About 39 disease-causing mutations in Gal (Table
3) and several polymorphisms have been described in
the world population [10,11,97^105]. Of these delete-
rious mutations, three are splice junction mutations,
two are duplications, three are insertions leading to
frameshifts, and two are premature chain termina-
tion mutations [11,105]. Of these, only the 641insT/
1627insG, the 896insC/1627insG, the dupl2/dupl2,
and Arg457ter/Arg457ter would be expected to result
in no functional protein. Twenty-nine missense mu-
tations are distributed uniformly over the entire
length of the gene. The active site catalytic nucleo-
phile, Glu268, which is totally conserved amongst
Gal species de¢ned to date (Fig. 5), has not been
identi¢ed as a mutated residue in any patient. Muta-
tions in Glu268 would predict the occurrence of pa-
tients with a severe phenotype of combined GM1
gangliosidosis and Morquio, type B. No such pa-
tients have been described to our knowledge. Candi-
dates for the second acid/base residue in the catalytic
mechanism are those that are completely conserved
in mature human Gal and the other family 35 hydro-
lases (only Glu186, Glu188, Glu339, and Asp332).
Asp332Asn Gal, when expressed in CHO cells and
puri¢ed to homogeneity, results in a marked reduc-
tion in catalytic activity consistent with it having a
role in the active site [74]. Asp491Asn, which has not
been expressed, and Glu632Gly, which is near the C-
terminal end of the protein and unlikely to play a
role in catalysis, are the only other mutated acidic
residues known. In the sequence immediately adja-
cent to Glu268, both Trp273 and Pro263 are highly
conserved and are involved in Gal de¢ciencies. The
most common mutation in Gal reported to date giv-
ing rise to Morquio disease, type B, involves conver-
sion of Trp273 to Leu and has been found in 12 (7
homoallelic; 5 heteroallelic) of the 15 patients re-
ported [106]. One Morquio, type B patient had the
Trp273Leu mutation on one allele with an Arg-
482His mutation on the other while Mosna et al.
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Table 3
Mutations in the L-galactosidase gene
Exon Nucleotide Residue Allelic residue Phenotype Origin Ref. Res. act./expresseda
1;1^25 T29C L10P Polymorph. Common [97]
ivs1, iT@75
new spl site
Adult Danish [101] Mother has 37.5% of N activity,
not expressed, see note 4
2;26^82 C145T R49C Unknown Infantile Japanese [99] Not stated
2;26^82 T152A I51T I51T Adult Japanese [97] expressed act 26.7% of N
activity; serum, 3.4%, see note 1
2;26^82 T155C S52P Unknown Juvenile English/
Scottish
[100] Not stated
2;26^82 G226A R59H R59H Infantile Brazilian [105] Not stated
2;26^82 C245T T82M Unknown Adult Danish [101] Father with T82M has 45.6% N
activity, expression gave 3^4% of
N activity, no WB
2;26^82 T297C Y83H Unknown [11] Not stated
2;26^82 nt254^276 Y316C Infantile Japanese [97] Not stated
dupl 1
2;26^82 gGTs aGT, frameshift spl2/spl2 Morquio Not stated [102]
spl. def., int 2 [11]
3;83^132 G413T R121S R208C Infantile Brazilian [105] Not expressed
3;83^132 G367A G123R G494C Infantile Japanese [97] Expression gave 0.3% N activity
but no Western blot
4,133^153 C442A R148S D332N Infantile English [74,112] Expression of R148S gave N
activity in COS cells, thus a
folding mutation. Patient also
polymorphic for S532G
6;185^245 C601T R201C Unknown LI/Juvenile Japanese [97] Expression gave 8.3% N activity,
see note 2
6;185^245 C601T R201C R201C LI/Juvenile Japanese [97] 6.9%, 3.4% see note 2
[102]
6;185^245 G602A R201H P263S Adult Not stated [97] Expression gave 46.5% N
activity, but no Western blot
6;185^245 G602A R201H N318H Juvenile/
morquio
Greek [102] Expression gave 46.5% N
activity, but no Western blot
6;185^245 C622T R208C R208C Infantile English/
European
[100] Expressed mutation gave 6 1%
activity but no Western blot
R208C 1627insG Brazilian [105]
6;185^245 641insT frameshift 1627insG Infantile Brazilian [105] Not expressed
6;185^245 T647C V216A Unknown Infantile English [74,112] Not expressed
6;185^245 G768A V240M V240M Infantile Brazilian [105] Not expressed
6;185^245 caas gAA spl.
def., int 6
Unknown [11] Not stated
7;246^264 CCCsTCC P263S R201H Adult Not stated [11,102] Expressed mutation gave 0.0%
activity, but no Western blot
8;265^308 TG817/18CT W273L R482H Morquio American [104] See note 3; puri¢ed mutant
enzyme low residual activity
W509C Morquio American
8;265^308 896insC frameshift 1627insG Infantile Brazilian [105] Not expressed
9;309^318 A947G Y316C dupl1 Infantile Japanese [97] Not expressed
9;309^318 AATsCAT N318H R201H Juvenile/
morquio
Greek [102] Not expressed
10;319^356 GACsAAC D332N R148S Infantile English [74,112] Expression of D332N gave,1% N
activity in COS-1 and CHO cells
active site mutation
BBADIS 61880 10-9-99
J.W. Callahan / Biochimica et Biophysica Acta 1455 (1999) 85^10398
Table 3 (continued)
Mutations in the L-galactosidase gene
Exon Nucleotide Residue Allelic residue Phenotype Origin Ref. Res. act./expresseda
10;319^356 CGAsTGA R351ter R351ter Infantile Venezuelan [74,112]
11;357^381
11/12 nt1069^1233 dupl2 Unknown Infantile Japanese [97]
11/12 nt1069^1233 dupl2 dupl2 Infantile Japanese [98] 0.7^1.6%, large mRNA
12;382^410
13;411^449
14;450^493 C1369T R457ter R457ter Infantile Japanese [99]
14;450^493 C1369A R457Q I51T Adult Japanese [97] Expressed mutation gave 0.6%
N activity but no Western blot
14;450^493 G1445A R482H R482H Infantile Italian [107] Not expressed
14;450^493 G1445A R482H W273L Morquio American [102] Not expressed
[104] Expressed mutation gave 0.4%
N activity but no Western blot
14;450^493 G1521A D491N 1627insG Infantile Brazilian [105] Not expressed
15;494^578 G1480T G494C G123R Infantile Japanese [97] Not expressed
15;494^578 G1527T W509C W273L Morquio American [104] Not expressed
15;494^578 A1594G S532G several None Common [74,112] Polymorphism giving 75^95% of
normal activity on expression
15;494^578 1627insG frameshift R59H Infantile Brazilian [105] Not expressed
15;494^578 A1733G K578R R208C Infantile English [100] Expressed mutation gave 6 4%
of control activity, but no
Western blot
15;494^578 A1733G K578R R208C Infantile Mexican [100] Expressed mutation gave 6 4%
of control activity, but no
Western blot
16;579^677 G1769A R590H R208C Juvenile English/
German
[100] Expressed mutation gave 6 1%
of control activity, but no
Western blot
16;579^677 A1828G T610A R208C Juvenile Italian/Puerto
Rican
[100] Not expressed
16;579^677 A1895G E632G R208C Juvenile English/
Scottish
[100] Expressed mutation gave 6 1%
of control activity, but no
Western blot
16;579^677 A1953G K655R Unknown Juvenile English [100] Not expressed
Single-letter abbreviations are used to identify the amino acid residues. Abbreviations used: WB, Western blot; N, normal.
Note 1: I51T is a common mutation in adults with GM1. The expressed precursor was not phosphorylated, there was no e¡ect of the
co-expressed protective protein, enzyme was not processed and E64 had no e¡ect [94]. Case 7 in [97] same as A/C in [98]. Clinical
data on adults found in [10]. I51T when expressed gave 13.8% of normal according to Ishii et al. [102].
Note 2: R201C is considered a common mutation in late infantile/juvenile patients. In one report, on transfection, there was a de-
creased amount of precursor (folding mutation?), the protective protein had no e¡ect on stability, and the presence of the thiol pro-
tease inhibitor, E64, increased the amount of precursor [93]. Ishii et al. [102] reported that this mutation gave a 3.4% residual activity.
Note 3: The W273L mutation is considered a common mutation for Morquio B. Although there is reduced activity this mutation re-
sults in ample amounts of precursor, protective protein helps processing and there is an increase with E64 [94]. Ishii et al. [102] re-
ported this mutation gave 7.9% residual activity.
Note 4: The insertion of a T at position 75 alters the usual 5P splice donor site but activates a new downstream donor splice site.
This results in a 20 bp insertion of intron sequence in the mRNA resulting eventually in a frameshift and premature termination of
translation.
aNucleotide positions use the D’Azzo clone, and are marked from the initiating ATG.
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[107] described a severely a¡ected type 1, GM1 pa-
tient who was homozygous for Arg482His. Therefore
the features of the Morquio, B phenotype must be
due to the least severe of the two mutations, namely
Trp273Leu. We expressed the Trp273Leu mutation
in permanently-transfected CHO cells and found a
markedly diminished catalytic activity in the puri¢ed
precursor (speci¢c activity 0.31 Wmol/h per mg pro-
tein compared to the wild-type activity of 500^700
Wmol/h per mg protein) [74] in accord with our ear-
lier prediction [71]. Fukuhara et al. [108] found an
altered Km and Vmax for this mutant expressed in
insect cells which con¢rms and extends these ¢nd-
ings. We postulated that Trp273 plays an important
role in substrate binding [71] (Fig. 4) by promoting
‘stacking’ between the planar indole ring and the
pyranose backbone stabilizing the enzyme^substrate
complex [109]. Based on sequence homologies, hu-
man Gal may have a structure similar to that of 6-
phospho-L-galactosidase from Lactococcus lactis
which has been crystallized and is also a member
of the 4/7 superfamily. It hydrolyzes lactose-6-phos-
phate (glucose-galactose-6-phosphate) [110,111]. The
crystal structure shows it to contain a (LK)8-barrel
structure with a central core, a catalytic mechanism
identical to human Gal where unique conformational
features bring the two acidic residues close enough to
catalyze the reaction. This mechanism also docu-
ments hydrophobic stacking roles for tryptophan
and tyrosine residues analogous to that proposed
for human Gal Trp273. Interestingly, the same
unique conformational features may be provided by
Pro263 in the human enzyme which is predicted to
facilitate substrate binding and may be consistent
with the milder GM1 phenotype seen (Table 3).
Six mutations (5 occur in GM1, 1 in Morquio, B)
introduce new cysteine residues which would a¡ect
cystine bond formation and would be predicted to
result in a misfolded conformation (the mutant pre-
cursor would not exit the ER). For example, Oshima
et al. [94] expressed the Arg201Cys mutation and
showed it produced a misfolded protein, as expected,
while the Arg201His mutation alone was reported to
produce 46.5% of the normal level of activity. Four
mutations occur in exon 16 near the C-terminal
(from residue 579^677), a region which is thought
to be essential for complex formation in the lysosome
but which is presumed to be lost (there is no direct
evidence to date) from the mature protein during
enzyme processing to its mature form (see above).
Consistent with this notion, mutations in this region
have been found only in patients with the later onset
type 2, GM1 gangliosidosis.
Approximately 16 mutations have been expressed
by transfection into host cells. In addition to Asp-
332Asn, and the Trp273Leu, cited above, we found
the Arg148Ser mutation produced a fully active en-
zyme that was su⁄ciently misfolded that it could not
exit the ER and was likely rapidly degraded while the
Ser532Gly polymorphism was fully active and was
appropriately targeted as expected [112]. Oshima et
al. al [94] found that the expressed precursor contain-
ing the I51T mutation was not phosphorylated prop-
erly. Many other mutations have been examined only
for their e¡ect on enzyme activity [10,11,97,100,105].
In our hands, all of the approximately 20 GM1-gan-
gliosidosis and Morquio, B patients we have exam-
ined display markedly decreased levels of immuno-
reacting material [59,112,113]. Since Glu268, Asp332
and Trp 273 are the only residues known to date that
are involved in catalytic activity although many
others also likely play a role, it seems certain that
the majority of the missense mutations have their
major e¡ect on enzyme folding resulting in degrada-
tion in the ER such that only small amounts of pre-
cursor arrive in the lysosome and are available for
processing to the mature form.
10. Pathophysiological bases of GM1 gangliosidosis
and Morquio, type B: a hypothesis
It can be predicted that if a 5^10% residual Gal
activity as seen in Morquio disease, type B, gives rise
to keratan sulfate storage, then a 0^5% residual ac-
tivity would be expected to give rise to storage of all
natural substrates of the enzyme (GM1 ganglioside,
galactose-terminal neutral oligosaccharides and ker-
atan sulfate). However, this does not seem to hap-
pen. Furthermore, infantile patients with GM1 gan-
gliosidosis have unequivocal skeletal abnormalities at
least as severe as seen in Morquio B disease, but they
do not display the same massive storage of keratan
sulfate, while patients with a primary keratan sulfate
storage do not show massive accumulation of GM1
ganglioside in the brain. To reconcile the exclusiv-
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ity of storage substances in these diseases, one or
more of the following explanations seem correct. (i)
Trp273 is important, if not essential, for binding to
either the terminal galactose or the terminal disac-
charide of keratan sulfate, probably because this dis-
accharide contains a 6-sulfated-N-acetylglucosamine,
to secure it at the active site. Trp273 is less critical in
the binding of other substrates. There is some evi-
dence in favor of this [67,68,74,108]. (ii) Binding of
keratan sulfate at the active site is favored over oli-
gosaccharides. Binding of GM1 ganglioside is least
favored as it requires association with the activator
protein, saposin B. Any mutation a¡ecting the sap-
osin binding site would reduce the ability to bind
saposin^GM1 complex and abolishing hydrolysis
GM1 ganglioside. GM1 gangliosidosis would result.
In addition, many mutations found in GM1 ganglio-
sidosis are heteroallelic with one mutation being of
the missense type, but none involve Trp273. (iii) Mis-
sense mutations a¡ect folding but misfolded Gal may
be catalytically active as we have shown for
Arg148Ser. In these instances, we assume su⁄cient
enzyme exits the ER, reaches the lysosome and cata-
lyzes hydrolysis of the most favorably bound sub-
strates, i.e., keratan sulfate. Therefore, keratan sul-
fate out-competes oligosaccharides and GM1
ganglioside for the residual enzyme present. Since
hydrolysis of keratan sulfate does not require saposin
B, and the turnover rate for maintenance is predicted
to be lower than for GM1 ganglioside, the catalytic
requirements are more easily met even by the lowest
residual enzyme level and keratan sulfate metabolism
can occur. (iv) No studies have been reported on the
role of S-Gal in these diseases. Our preliminary data
suggest it is involved in the formation of extracellular
matrix and may be uniquely involved in extracellular
keratan sulfate deposition. Expression in S-Gal of
the mutations which a¡ect Gal are required to an-
swer this question. Finally, some of the mutations
listed in Table 3 (homozygous chain termination mu-
tations) are predicted to disrupt synthesis of viable
forms of both Gal and S-Gal and where found the
patients should manifest the features of both GM1
gangliosidosis and Morquio B disease. However, the
reports do not mention the coincidence of clinical
features of both diseases. Further work is therefore
needed at the clinical, biochemical and molecular
levels to resolve these questions.
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